Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2013 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Chromatin Remodeling in Patient-Derived Colorectal Cancer Models.
Conference Advanced science (Weinheim, Baden-Wurttemberg, Germany) · April 2024 Patient-Derived Organoids (PDO) and Xenografts (PDX) are the current gold standards for patient-derived models of cancer (PDMC). Nevertheless, how patient tumor cells evolve in these models and the impact on drug response remains unclear. Herein, the trans ... Full text CiteLongitudinal intravital imaging of mouse placenta.
Journal Article Sci Adv · March 22, 2024 Studying placental functions is crucial for understanding pregnancy complications. However, imaging placenta is challenging due to its depth, volume, and motion distortions. In this study, we have developed an implantable placenta window in mice that enabl ... Full text Open Access Link to item CiteWaldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal Article J Natl Compr Canc Netw · January 2024 The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of respo ... Full text Link to item CiteRecent Grants
A phase II safety and efficacy study of Selinexor in combination with bispecific antibody in patients with relapsed/refractory multiple myeloma
Clinical TrialPrincipal Investigator · Awarded by Karyopharm Therapeutics · 2025 - 2030A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplan
Clinical TrialPrincipal Investigator · Awarded by Stitching European Myeloma Network · 2024 - 2029An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458;anti-BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory Multiple Myeloma (LINKER-
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2029View All Grants
Education, Training & Certifications
Shanghai Second Medical University (China) ·
1991
M.D.